摘要
目的探讨右旋佐匹克隆辅助治疗精神分裂症睡眠障碍的临床疗效及安全性。方法将100例精神分裂症伴睡眠障碍的患者随机分为两组，每组50例，两组均口服阿立哌唑治疗，研究组联合右旋佐匹克隆治疗，对照组联合阿普唑仑治疗，研究组脱落3例，对照组脱落4例，脱落病例不计入研究结果，观察3周。于治疗前及治疗1周、2周、3周末采用阳性与阴性症状量表、副反应量表评定临床疗效及不良反应；治疗前及治疗3周末采用匹兹堡睡眠质量指数评定睡眠状况。结果治疗后两组阳性与阴性症状量表总分、匹兹堡睡眠质量指数总分及各因子分均较治疗前有显著下降（P〈0．01），睡眠时间均较治疗前显著延长（P〈0．01）；研究组治疗后日间功能障碍因子分较对照组下降更显著（P〈0．05）；治疗3周末，研究组显效率68．09％、有效率93．62％，对照组为60．87％、91．30％，两组差异无显著性（X＾2＝0．53，P〉0．05）。研究组嗜睡、头昏发生率显著低于对照组（X＾25．62、4．57，P〈0．05）。结论右旋佐匹克隆组辅助治疗精神分裂症睡眠障碍疗效显著，与阿普唑仑相当，但安全性优于阿普唑仑。
Objective To explore the clinical efficacy and safety of eszopiclone adjunctive treatment for sleep disorders of schizophrenia. Methods One hundred schizophrenics with sleep disorders were randomly assigned to two groups of 50 patients each, both groups took orally aripiprazole, research group was plus eszopiclone and control group plus alprazolam for 3 weeks, three dropped out in the research and 4 in the control group, and lost cases were not included into finding. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） before treatment and at the end of the 1^st, 2^nd and 3^rd week; sleep status was assessed with the Pittsburgh Sleep Quality Index （PSQI） before treatment and at the end of the 3^rd week. Results After treatment, the PANSS and PSQI total and all factors＇ scores lowered more significantly （P〈0.01） and sleep time prolonged more significantly （P〈0.01） in both groups compared with pretreatment; daytime dysfunction score lowered more significantly in the research than in the control group after treatment （P〈0.05） ; at the end of the 3ra week, obvious effective and effective rates were 68.09% and 93.62% in the ersearch and 60.87% and 91.30% in the control group, respectively, which showed no significant differences （X^2=0.53,P〉0.05）. Incidences of hypersomnia and dizzness were lower in the research than in the control group （X^2=5.62,4.57,P〈0.05）. Conclusion Eszopiclone adjunctive treatment for sleep disorders of schizophrenia has significant curative effect equivalent to alprazolam, but has an advantage over alprazolam in safety.
出处
《临床心身疾病杂志》
CAS
2011年第5期392-394,共3页
Journal of Clinical Psychosomatic Diseases
